HC Wainwright Boosts Earnings Estimates for Innate Pharma

Key Points

• HC Wainwright raised Innate Pharma’s FY2026 EPS estimate to a loss of $0.53 per share from its previous $0.79 loss forecast, while maintaining a “Buy” rating.
• The firm projects smaller losses in subsequent years: $0.45 per share in FY2027 and $0.08 per share in FY2028. Analysts overall assign Innate Pharma a “Moderate Buy” consensus rating with a $6.67 target price.
• Innate Pharma shares opened at $1.80, compared with a 52-week range of $1.17 to $2.71. The biotechnology company is developing cancer immunotherapies, including its lacutamab antibody program.

Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA - Free Report) - Stock analysts at HC Wainwright increased their FY2026 EPS estimates for Innate Pharma in a research report issued on Monday, September 21st. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($0.53) per share for the year, up from their previous estimate of ($0.79). HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for Innate Pharma's current full-year earnings is ($0.79) per share. HC Wainwright also issued estimates for Innate Pharma's FY2027 earnings at ($0.45) EPS and FY2028 earnings at ($0.08) EPS.

IPHA has been the topic of a number of other reports. Weiss Ratings raised shares of Innate Pharma from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, June 26th. UBS Group reiterated a "buy" rating on shares of Innate Pharma in a research note on Tuesday, August 11th. Leerink Partners upgraded Innate Pharma from a "market perform" rating to an "outperform" rating and set a $4.00 target price on the stock in a research report on Tuesday, August 11th. BTIG Research reissued a "buy" rating and set a $9.00 price target on shares of Innate Pharma in a research report on Thursday, September 17th. Finally, Citigroup upgraded shares of Innate Pharma from a "buy" rating to an "outperform" rating in a research note on Tuesday, August 11th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Innate Pharma currently has a consensus rating of "Moderate Buy" and a consensus target price of $6.67.

Innate Pharma Stock Performance

Shares of IPHA stock opened at $1.80 on Wednesday. The stock's 50-day simple moving average is $1.98 and its 200-day simple moving average is $1.75. Innate Pharma has a fifty-two week low of $1.17 and a fifty-two week high of $2.71.

Innate Pharma Company Profile

Innate Pharma SA is a biotechnology company headquartered in Marseille, France, focused on developing immunotherapies for cancer. Founded in 1999, the company uses its expertise in the biology of natural killer cells and other components of the innate immune system to develop antibody-based treatments designed to help the immune system recognize and attack cancer cells.

Innate Pharma's pipeline includes lacutamab, an investigational antibody targeting KIR3DL2 for certain forms of cutaneous T-cell lymphoma and other T-cell malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.